Osteosarcoma is one of the most common malignancies in bones and is often found in limbs. Until now, it is not clear why osteosarcoma is rare in the spine. On the other hand, previous biological characteristics study about osteosarcoma of spine was also rare because of its low incidence. To explore the biology of spinal osteosarcoma, a stable osteosarcoma cell line derived from spine is necessary.
A novel osteosarcoma cell line named NEO217 was established from spinal osteosarcoma tissues obtained from a Chinese male patient. We performed a series of experiments to investigate the biological properties of NEO217, including cell morphology, the kinetics of cell growth, biomarkers and tumorigenicity.
The cell line NEO217 was passaged in vitro for more than 50 generations. Ultramicroscopic structural features of these cells were consistent with the pleomorphism characteristic of cancer cells. The average cell doubling time was 26 h. The chromosomal morphology was that of a human karyotype, with the number of chromosomes more than 80. NEO217 cells and available osteosarcoma cell lines such as MG-63 and MNNG/HOS were all CD29+CD59+ phenotype as detected by flow cytometry. Inoculation of NEO217 cells to immunodeficient mice led to tumor formation. The biological and molecular properties of NEO217 cell line are not exactly the same as some human osteosarcoma cell lines derived from the extremities.
We have established a novel osteosarcoma cell line NEO217 derived from the spine, which will provide a useful model for biological or therapeutical studies of spinal osteosarcoma.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Allen MD et al (2011) Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol 223:646–658. doi:10.1002/path.2833
Baumhoer D (2013) Molecular characterization of osteosarcomas. Der Pathologe 34(Suppl 2):260–263. doi:10.1007/s00292-013-1823-9
Billiau A, Edy VG, Heremans H, Van Damme J, Desmyter J, Georgiades JA, De Somer P (1977) Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother 12:11–15
Brakebusch C, Fassler R (2005) beta 1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev 24:403–411. doi:10.1007/s10555-005-5132-5
Briest F, Grabowski P (2015) The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treat Rev. doi:10.1016/j.ctrv.2015.03.006
Cho JH, Lee SJ, Oh AY, Yoon MH, Woo TG, Park BJ (2015) NF2 blocks Snail-mediated p53 suppression in mesothelioma. Oncotarget 6:10073–10085. doi:10.18632/oncotarget.3543
Dahlin DC, Coventry MB (1967) Osteogenic sarcoma. A study of six hundred cases. J Bone Jt Surg Am 49:101–110
Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y (2010) Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Mol Cell Biol 30:3981–3993. doi:10.1128/mcb.01284-09
Ek ET, Dass CR, Choong PF (2006) Commonly used mouse models of osteosarcoma. Crit Rev Oncol Hematol 60:1–8. doi:10.1016/j.critrevonc.2006.03.006
Fan TM (2010) Animal models of osteosarcoma. Expert Rev Anticancer Ther 10:1327–1338. doi:10.1586/era.10.107
Grzesiak JJ et al (2011) Knockdown of the beta(1) integrin subunit reduces primary tumor growth and inhibits pancreatic cancer metastasis. Int J Cancer J Int du Cancer 129:2915. doi:10.1002/ijc.25942
Heo SH, Kwak J, Jang KL (2015) All-trans retinoic acid induces p53-depenent apoptosis in human hepatocytes by activating p14 expression via promoter hypomethylation. Cancer Lett. doi:10.1016/j.canlet.2015.03.036
Ji L et al (2015) Mutant p53 promotes tumor cell malignancy by both positive and negative regulation of TGF-beta pathway. J Biol Chem. doi:10.1074/jbc.M115.639351
Kager L et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21:2011–2018. doi:10.1200/jco.2003.08.132
Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN (1999) Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer 86:1602–1608
Lammli J et al (2012) Expression of vascular endothelial growth factor correlates with the advance of clinical osteosarcoma. Int Orthop 36:2307–2313. doi:10.1007/s00264-012-1629-z
Li B, Chu X, Gao M, Xu Y (2011) The effects of CD59 gene as a target gene on breast cancer cells. Cell Immunol 272:61–70. doi:10.1016/j.cellimm.2011.09.006
Li G, Cai M, Fu D, Chen K, Sun M, Cai Z, Cheng B (2012) Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem 30:1481–1490. doi:10.1159/000343336
Martin JW, Squire JA, Zielenska M (2012) The genetics of osteosarcoma. Sarcoma 2012:627254. doi:10.1155/2012/627254
Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ (1990) Human protectin (CD59), an 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71:1–9
Meyers PA (2009) Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Rev Anticancer Ther 9:1035–1049. doi:10.1586/era.09.69
Mialou V et al (2005) Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome–the French pediatric experience. Cancer 104:1100–1109. doi:10.1002/cncr.21263
Miiji LN et al (2011) C-kit expression in human osteosarcoma and in vitro assays. Int J Clin Exp Pathol 4:775–781
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 115:1531–1543. doi:10.1002/cncr.24121
Mlynarczyk C, Fahraeus R (2014) Endoplasmic reticulum stress sensitizes cells to DNA damage-induced apoptosis through p53-dependent suppression of p21(CDKN1A). Nat Commun 5:5067. doi:10.1038/ncomms6067
Mohseny AB et al (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294–305. doi:10.1002/path.2603
Nada OH, Ahmed NS, Abou Gabal HH (2014) Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 9:72. doi:10.1186/1746-1596-9-72
Ozaki T et al (2002) Osteosarcoma of the spine: experience of the Cooperative Osteosarcoma Study Group. Cancer 94:1069–1077
Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J (2015) Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci USA 112:E1220–E1229. doi:10.1073/pnas.1416318112
Ponten J, Saksela E (1967) Two established in vitro cell lines from human mesenchymal tumours International journal of cancer Journal international du cancer 2:434–447
Rhim JS, Park DK, Arnstein P, Huebner RJ, Weisburger EK, Nelson-Rees WA (1975) Transformation of human cells in culture by N-methyl-N’-nitro-N-nitrosoguanidine. Nature 256:751–753
Schwab J et al (2012) Osteosarcoma of the mobile spine. Spine 37:E381–E386. doi:10.1097/BRS.0b013e31822fb1a7
Shives TC, Dahlin DC, Sim FH, Pritchard DJ, Earle JD (1986) Osteosarcoma of the spine. J Bone Jt Surg Am 68:660–668
Song J, Zhang J, Wang J, Cao Z, Wang J, Guo X, Dong W (2014) beta1 integrin modulates tumor growth and apoptosis of human colorectal cancer. Oncol Rep 32:302–308. doi:10.3892/or.2014.3168
Tang N, Song WX, Luo J, Haydon RC, He TC (2008) Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 466:2114–2130. doi:10.1007/s11999-008-0335-z
Taylor WF, Ivins JC, Pritchard DJ, Dahlin DC, Gilchrist GS, Edmonson JH (1985) Trends and variability in survival among patients with osteosarcoma: a 7-year update. Mayo Clin Proc 60:91–104
Van Nostrand JL, Brisac A, Mello SS, Jacobs SB, Luong R, Attardi LD (2015) The p53 target gene siva enables non-small cell lung cancer development. Cancer Discov. doi:10.1158/2159-8290.cd-14-0921
Wang H et al (2015) Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett 360:269–279. doi:10.1016/j.canlet.2015.02.028
Zhang GH, Xue WB, An YF, Yuan JM, Qin JK, Pan CX, Su GF (2015) Distinct novel quinazolinone exhibits selective inhibition in MGC-803 cancer cells by dictating mutant p53 function. Eur J Med Chem 95:377–387. doi:10.1016/j.ejmech.2015.03.053
Conflict of interest
The corresponding author Dr. Jianru Xiao has received research grants from funding listed below in Funding Source. The authors declare that they have no conflict of interest.
This study was funded by Bone Tumors and Nervous System Tumors Biobank Project of Shanghai (12DZ2295103), Bone Tumor Sample Databases and Digital Information Platform Project of Shanghai (08DZ2292800), and Shanghai Biobank Network of Common Human Tumor Tissue (12DZ2295100).
(1) Statement of human rights: All procedures performed in studies involving human participants were in accordance with the ethical standards of the Clinical Research Ethics Committee of Second Military Medical University and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Tumor tissues were obtained with informed consent, and this study was approved by the Clinical Research Ethics Committee of the Second Military Medical University. (2) Statement on the welfare of animals: All procedures performed in studies involving animals were in accordance with the ethical standards of the United Kingdom Coordinating Committee on Cancer Prevention Research’s Guidelines for the Welfare of Animals in Experimental Neoplasia. All experimental operations on animals were approved by the Animal Ethics Committees of the Second Military Medical University.
Informed consent was obtained from all individual participants included in the study.
About this article
Cite this article
Zhou, Z., Li, Y., Yan, X. et al. Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine. J Cancer Res Clin Oncol 143, 1959–1969 (2017). https://doi.org/10.1007/s00432-017-2448-9
- Cell line
- Tumor biology